|
1
|
Sadelain M, Brentjens R and Rivière I: The
basic principles of chimeric antigen receptor design. Cancer
Discov. 3:388–398. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brentjens RJ, Davila ML, Riviere I, Park
J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska
M, et al: CD19-targeted T cells rapidly induce molecular remissions
in adults with chemotherapy-refractory acute lymphoblastic
leukemia. Sci Transl Med. 5:177ra1382013. View Article : Google Scholar
|
|
3
|
Grupp SA, Kalos M, Barrett D, Aplenc R,
Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et
al: Chimeric antigen receptor-modified T cells for acute lymphoid
leukemia. N Engl J Med. 368:1509–1518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Davila ML, Riviere I, Wang X, Bartido S,
Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska
M, et al: Efficacy and toxicity management of 19-28z CAR T cell
therapy in B cell acute lymphoblastic leukemia. Sci Transl Med.
6:224ra1252014. View Article : Google Scholar
|
|
5
|
Kochenderfer JN, Dudley ME, Carpenter RO,
Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH,
Hardy NM, et al: Donor-derived CD19-targeted T cells cause
regression of malignancy persisting after allogeneic hematopoietic
stem cell transplantation. Blood. 122:4129–4139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kochenderfer JN, Dudley ME, Kassim SH,
Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ,
Hughes MS, Sherry RM, et al: Chemotherapy-refractory diffuse large
B-cell lymphoma and indolent B-cell malignancies can be effectively
treated with autologous T cells expressing an anti-CD19 chimeric
antigen receptor. J Clin Oncol. 33:540–549. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jolley B and Walker S: Chimeric antigen
receptor T-cell therapy for lymphomas. Hosp Pharm. 52:469–470.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barrett DM, Singh N, Porter DL, Grupp SA
and June CH: Chimeric antigen receptor therapy for cancer. Annu Rev
Med. 65:333–347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonifant CL, Jackson HJ, Brentjens RJ and
Curran KJ: Toxicity and management in CAR T-cell therapy. Mol Ther
Oncolytics. 3:160112016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu K, Tan S, Chai Y, Chen D, Song H,
Zhang CW, Shi Y, Liu J, Tan W, Lyu J, et al: Structural basis of
anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell
Res. 27:151–153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 369:134–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chong EA, Melenhorst JJ, Lacey SF, Ambrose
DE, Gonzalez V, Levine BL, June CH and Schuster SJ: PD-1 blockade
modulates chimeric antigen receptor (CAR)-modified T cells:
Refueling the CAR. Blood. 129:1039–1041. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maude SL, Frey N, Shaw PA, Aplenc R,
Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et
al: Chimeric antigen receptor T cells for sustained remissions in
leukemia. N Engl J Med. 371:1507–1517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee DW, Kochenderfer JN, Stetler-Stevenson
M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M,
Shah NN, et al: T cells expressing CD19 chimeric antigen receptors
for acute lymphoblastic leukaemia in children and young adults: A
phase 1 dose-escalation trial. Lancet. 385:517–528. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Batlevi CL, Matsuki E, Brentjens RJ and
Younes A: Novel immunotherapies in lymphoid malignancies. Nat Rev
Clin Oncol. 13:25–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang T, Cao L, Xie J, Shi N, Zhang Z, Luo
Z, Yue D, Zhang Z, Wang L, Han W, et al: Chimeric antigen
receptor-modified T cells for treatment of B cell malignancies in
phase I clinical trials: A meta-analysis. Oncotarget.
6:33961–33971. 2015.PubMed/NCBI
|
|
21
|
Makita S, Yoshimura K and Tobinai K:
Clinical development of anti-CD19 chimeric antigen receptor T-cell
therapy for B-cell non-Hodgkin lymphoma. Cancer Sci. 108:1109–1118.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen N, Morello A, Tano Z and Adusumilli
PS: CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one
approach for solid tumor immunotherapy. Oncoimmunology.
6:e12733022016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jaspers JE and Brentjens RJ: Development
of CAR T cells designed to improve antitumor efficacy and safety.
Pharmacol Ther. 178:83–91. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gargett T, Yu W, Dotti G, Yvon ES, Christo
SN, Hayball JD, Lewis ID, Brenner MK and Brown MP: GD2-specific CAR
T cells undergo potent activation and deletion following antigen
encounter but can be protected from activation-induced cell death
by PD-1 blockade. Mol Ther. 24:1135–1149. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li S, Siriwon N, Zhang X, Yang S, Jin T,
He F, Kim YJ, Mac J, Lu Z, Wang S, et al: Enhanced cancer
immunotherapy by chimeric antigen receptor-modified T cells
engineered to secrete checkpoint inhibitors. Clin Cancer Res.
23:6982–6992. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang AC, Postow MA, Orlowski RJ, Mick R,
Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al: T-cell
invigoration to tumour burden ratio associated with anti-PD-1
response. Nature. 545:60–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
John LB, Kershaw MH and Darcy PK: Blockade
of PD-1 immunosuppression boosts CAR T-cell therapy.
Oncoimmunology. 2:e262862013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Läubli H, Balmelli C, Bossard M, Pfister
O, Glatz K and Zippelius A: Acute heart failure due to autoimmune
myocarditis under pembrolizumab treatment for metastatic melanoma.
J Immunother Cancer. 3:112015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koelzer VH, Rothschild SI, Zihler D, Wicki
A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A and Mertz
KD: Systemic inflammation in a melanoma patient treated with immune
checkpoint inhibitors-an autopsy study. J Immunother Cancer.
4:132016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dubin K, Callahan MK, Ren B, Khanin R,
Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, et
al: Intestinal microbiome analyses identify melanoma patients at
risk for checkpoint-blockade-induced colitis. Nat Commun.
7:103912016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iwama S, De Remigis A, Callahan MK, Slovin
SF, Wolchok JD and Caturegli P: Pituitary expression of CTLA-4
mediates hypophysitis secondary to administration of CTLA-4
blocking antibody. Sci Transl Med. 6:230ra2452014. View Article : Google Scholar
|
